DrugBiological
Evolocumab clinical trials
Also written Repatha and AMG 145.
- studies test it
- 105
- open now
- 14
- in phase 3
- 36
- first study started
- 2010
Keep track of what changes. Save the evolocumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
103 studies that test it; most in 2019 (16); 2 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 11 |
| 2014 | 4 |
| 2016 | 7 |
| 2017 | 6 |
| 2018 | 10 |
| 2019 | 16 |
| 2020 | 8 |
| 2021 | 11 |
| 2022 | 7 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 7
- Phase 2
- 19
- Phase 3
- 36
- Phase 4
- 39
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 43 · Other 62
Amgen (40) · Johns Hopkins University (3) · Brigham and Women's Hospital (2) · NYU Langone Health (2) · Policlinico Casilino ASL RMB (2) · Leonardo Clavijo (2) · M.D. Anderson Cancer Center (1) · Assistance Publique - Hôpitaux de Paris (1)
Often tested with
Tested in the same studies.
Alirocumab (3) · Atorvastatin (3) · Ezetimibe (3) · Rosuvastatin (2) · Nivolumab (1) · Simvastatin (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Bempedoic acid (1)
Studies
Open first, then newest update. How each study uses evolocumab is read from its arms, and is right about nine times in ten.
Testing it · 105
- CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACSRecruitingPhase 4West China HospitalNCT07612774Written as Evolocumab
- Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute PancreatitisRecruitingNot applicableGeneral Hospital of Shenyang Military RegionNCT07388420Written as Evolocumab 140 MG/ML [Repatha]
- A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical AtheromaNot yet recruitingPhase 4AmgenNCT07803679Written as Evolocumab
- RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque RemodelingNot yet recruitingPhase 4Keqiang ZhaoNCT07819643Written as Intervention 1
- Mechanistic Clinical Trial of PCSK9 Inhibition for AAANot yet recruitingEarly Phase 1University of PennsylvaniaNCT06081153Written as Evolocumab
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1RecruitingPhase 4NYU Langone HealthNCT05641753Written as Evolocumab Cartridge
- The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV RiskRecruitingPhase 4Brigham and Women's HospitalNCT05152888Written as Evolocumab
- Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial InfarctionRecruitingNot applicableBeijing Luhe HospitalNCT06364124Written as evolocumab
- Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)Not yet recruitingNot applicableJena University HospitalNCT05587621Written as statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
- High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized StudyRecruitingPhase 4Wuhan Union Hospital, ChinaNCT05585151Written as Evolocumab 140 MG/ML
- Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid MetabolismNot yet recruitingEarly Phase 1Region StockholmNCT06140095Written as Evolocumab
- Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary SyndromeRecruitingPhase 4Korea University Anam HospitalNCT04719221Written as Evolocumab
- Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and CancerNot yet recruitingPhase 4Xiang XieNCT05976893Written as Evolocumab
- Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)RecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT05741086Written as Evolocumab
- A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)Active, not recruitingPhase 2M.D. Anderson Cancer CenterNCT06284564Written as Evolocumab
- Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.CompletedPhase 1AmgenNCT07545226Written as Evolocumab Drug Substance A (Test)
- Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous DoseCompletedPhase 1AmgenNCT07422285Written as Evolocumab Drug Substance A
- Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled TrialCompletedPhase 4The Affiliated Hospital of Xuzhou Medical UniversityNCT07295366Written as Evolocumab(420 mg injections)
- Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeCompletedPhase 3AmgenNCT03872401Written as Evolocumab
- Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCITerminatedPhase 4Henan Institute of Cardiovascular EpidemiologyNCT05613426Written as Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]
See all 105 studies that test evolocumab →
Given in every arm · 5 — evolocumab is usual care beside what is tested
- YN001-004 in Patients With Coronary Atherosclerosis in AustraliaTerminatedPhase 2Beijing Inno Medicine Co., Ltd.NCT06700720Written as Evolocumab
- Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study EnrollmentCompletedPhase 3AmgenNCT02585895Written as Evolocumab
- Open Label Study of Long Term Evaluation Against LDL-C TrialCompletedPhase 2AmgenNCT01439880Written as Evolocumab
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4CompletedPhase 3AmgenNCT02634580Written as Evolocumab
- Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor TherapyCompletedPhase 2Esperion Therapeutics, Inc.NCT03193047Written as evolocumab
As the comparator · 4 — what is tested is compared with evolocumab
- A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart DiseaseCompletedPhase 2Novo Nordisk A/SNCT04992065Written as Evolocumab 140 mg/mL, Repatha®
- Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD PatientsCompletedPhase 3LIB Therapeutics LLCNCT04790513Written as evolocumab
- Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFHCompletedPhase 3LIB Therapeutics LLCNCT04034485Written as evolocumab
- An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High CholesterolCompletedPhase 2Novartis PharmaceuticalsNCT03060577Written as Evolocumab
Codes
What other systems call evolocumab · ClinicalTrials.gg INT006205
- MeSH (NLM) C577155evolocumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) LKC0U3A8NJEVOLOCUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1665684Confirmed FDA, Wikidata
- Wikidata Q15623825evolocumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174672EvolocumabOne source FDA
- DrugBank DB09303One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C577155 | evolocumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | LKC0U3A8NJ | EVOLOCUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1665684 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15623825 | evolocumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174672 | Evolocumab | One source FDA |
| DrugBank | DB09303 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.